In this issue:
- Thrombotic events after Pfizer’s COVID-19 vaccine in NZ
- 36-month clinical outcomes of VTE
- 6 vs. 3 months of rivaroxaban for symptomatic isolated distal DVT
- Intermediate- vs. low-dose LMWH in pregnant/post partum women with prior VTE
- Anticoagulants for cancer-associated thrombosis
- Catheter-directed thrombolysis vs. anticoagulation for acute intermediate- to high-risk PE
- Recovery of RV function after intermediate-risk PE
- Alveolar dead space increases during exercise in HFPEF
- Traditional mind-body movement therapies for chronic cardiopulmonary dyspnoea
- Sotatercept for PAH
Please login below to download this issue (PDF)